Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology ...

One of the first HPV self-collection solutions has been approved by the FDA, which can identify women at risk of developing ...

Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.

Lisocabtagene maraleucel was approved by the FDA to treat adults with relapsed/refractory follicular lymphoma who were ...

Patients with triple-negative breast cancer with an increased TIL count in breast tissue were more likely to have an improved ...

Meaghan Mooney, B.S.N., RN, OCN, discusses the steps she takes to be an extraordinary healer every day and offers advice for ...

Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with ...

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 ...

Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations. Patients with previously treated advanced ...

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment. Venetoclax (Venclexta) resulted in ...

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Patients with chronic lymphocytic ...